Author | Tumor Types | Technologies Used | Patients Profiled | Patients Treated | % Impact on Treatment Choice | Patients evaluable for Clinical Benefit | Measure of Clinical Benefit | Patients with Clinical Benefit | % Clinical Benefit (compared to Patients Evaluable) | % Clinical Utility (compared to Patients Profiled) |
Academic Approaches |
Tsimberidou et al.[46] | Refractory Solid Tumors | SS | 1144 | 175 | 15 | 175 | RECIST Response | 47 | 27 | 4 |
Stockley et al.[47] | Refractory Solid Tumors | NGS | 1640 | 245 | 5 | 84 | RECIST Response | 16 | 19 | 1 |
Le Tourneau et al.[48] | Refractory Solid Tumors | IHC, NGS | 496 | 195 | 39 | 99 | Disease control rate | 45 | 45 | 9 |
Massard et al.[49] Refractory Solid Tumors | CGH, NGS, WES, RNAseq | 639 | 141 | 22 | 141 | RECIST Response | 47 | 33 | 7 | |
Andrè et al.[50] | Refractory Breast Cancers | CGH, SS | 297 | 48 | 16 | 43 | RECIST Response | 13 | 30 | 4 |
Cousin et al.[51] | Refractory Solid Tumors | NGS, CGH | 568 | 86 | 15 | 65 | Disease control rate | 31 | 48 | 5 |
Dienstmann et al.[52] | Refractory Colorectal Cancers | IHC, SS | 254 | 68 | 27 | 68 | CR/PR SD > 4 months | 11 | 16 | 4 |
Kim et al.[53] | Refractory Colorectal Cancers | NGS, CNV | 407 | 103 | 25 | 103 | RECIST Response | 44 | 43 | |
Tanabe et al.[54] | Refractory Solid Tumors | NGS | 131 | 29 | 7 | 9 | RECIST Response | 3 | 33 | 2 |
TOTAL | | | 5576 | 1090 | 20 | 787 | | 257 | 33 | 5 |
Commercial Approaches |
Caris Molecular Intelligence® |
Von Hoff et al.[8] | Refractory Solid Tumors | IHC, ISH, DNAMA, SS | 84 | 66 | 79 | 66 | PFS Ratio ≥ 1.3 | 18 | 27 | 21 |
Jameson et al.[9] | Refractory Breast Cancer | IHC, ISH, DNAMA, SS | 28 | 25 | 89 | 25 | PFS Ratio ≥ 1.3 | 13 | 52 | 46 |
Epelbaum et al.[10] | Refractory Pancreatic Cancer | IHC, ISH, DNAMA, SS | 55 | 30 | 55 | 24 | PFS Ratio ≥ 1.3 | 9 | 38 | 16 |
Dean et al.[11] | Refractory Solid Tumors | IHC, ISH, DNAMA, SS, NGS | 54 | 54 | 100 | 37 | PFS Ratio ≥ 1.3 | 22 | 60 | 41 |
Popovtzer et al.[12] | Metastatic Adenoid Cystic Carcinoma | IHC, ISH, DNAMA, SS | 14 | 11 | 79 | 11 | CR/PR/SD>6 months | 8 | 73 | 57 |
Ramanathan et al.[13] | Refractory Pancreatic Cancers | IHC, ISH, DNAMA, SS | 49 | 35 | 71 | 34 | OS>6 months | 14 | 41 | 29 |
Purim et al.[14] | Refractory Gastric Cancers | IHC, ISH, DNAMA, SS | 46 | 28 | 61 | 24 | PFS Ratio ≥ 1.3 | 7 | 29 | 15 |
Seeber et al.[15] | Refractory Solid Tumors | IHC, ISH, NGS | 58 | 40 | 69 | 40 | PFS Ratio ≥ 1.3 | 22 | 55 | 38 |
El Ahmadie et al.[16] | Refractory Solid Tumors | IHC, ISH, NGS | 73 | 69 | 95 | 59 | CR/PR/SD | 41 | 69 | 56 |
Chahine et al.[17] | Refractory Solid Tumors | IHC, ISH, NGS | 34 | 27 | 79 | 23 | PFS Ratio ≥ 1.0 | 15 | 65 | 44 |
El Nahas et al.[18] | Refractory Solid Tumors | IHC, ISH, NGS | 39 | 26 | 67 | 22 | CR/PR/SD | 15 | 68 | 38 |
TOTAL | | | 534 | 411 | 77 | 365 | | 184 | 50 | 34 |
FoundationOne® |
Ferreira et al.[19] | Refractory Solid Tumors | NGS | 66 | 11 | 17 | 11 | CR/PR/SD>6 months | 3 | 27 | 5 |
Ganesan et al.[20] | Refractory Breast Cancers | NGS | 106 | 16 | 15 | 16 | CR/PR/SD>6 months | 5 | 31 | 5 |
Brandao Moreira et al.[21] | Refractory Breast Cancers | NGS | 20 | 9 | 45 | 9 | Objective response | 7 | | |
Brandao Moreira et al.[22] | Refractory Gastrointestinal Cancers | NGS | 32 | 6 | 19 | 6 | Objective response | 4 | | |
Wheler et al.[23] | Refractory Solid Tumors | NGS | 500 | 110 | 22 | 110 | CR/PR/SD>6 months | 18 | 16 | 5 |
Schwaederle et al.[24] | Refractory Solid Tumors | NGS | 347 | 74 | 25 | 74 | CR/PR/SD>6 months | 27 | 36 | 8 |
Sohal et al.[25] | Refractory Solid Tumors | NGS | 223 | 24 | 11 | 24 | CR/PR/SD>6 months | 7 | 29 | 3 |
Blumenthal et al.[26] | Refractory Glioblastoma | NGS | 43 | 13 | 30 | 13 | RECIST Response | 0 | 0 | 0 |
Rodriguez-Rodriguez et al.[27] | Gynecological Cancers | NGS | 69 | 25 | 36 | 23 | CR/PR/SD/CB | 16 | 70 | 23 |
Johnson et al.[28] | Refractory Solid Tumors | NGS | 103 | 18 | 17 | 18 | CR/PR/SD>6 months | 6 | 33 | 6 |
Hirschfield et al.[29] | Refractory Solid Tumors | NGS | 100 | 31 | 31 | 31 | CR/PR/SD>6 months | 7 | 23 | 7 |
Groisberg et al.[30] | Sarcomas | NGS | 102 | 16 | 16 | 16 | CR/PR/SD>6 months | 8 | 50 | 8 |
Koenig et al.[31] | Refractory Gastrointestinal Malignancies | NGS | 271 | 14 | 5 | 14 | Disease Control Rate | 3 | 21 | 1 |
Dhir et al.[32] | Refractory Solid Cancers | NGS | 97 | 13 | 13 | 13 | CR/PR/SD>6 months | 7 | 54 | 7 |
Yuan et al.[33] | Refractory Breast Cancers | NGS | 44 | 23 | 52 | 16 | CR/PR/SD>6 months | 7 | 44 | 16 |
Grenader et al.[34] | Refractory Solid Cancers | NGS | 30 | 10 | 33 | 10 | CR/PR/SD>6 months | 3 | 30 | 10 |
Gunderson et al.[35] | Gynecological Cancers | NGS | 62 | 6 | 4 | 4 | CR/PR/SD>6 months | 2 | 50 | 3 |
Groisberg et al.[36] | Rare Cancers | NGS | 95 | 9 | 9 | 9 | Disease Control rate | 7 | 78 | 7 |
Dalton et al.[37] | Refractory Solid Cancers | NGS | 155 | 24 | 15 | 24 | CR/PR/SD>6 months | 6 | 25 | 4 |
Sicklick et al.[38] | Treatment-naïve Cancers | NGS | 47 | 17 | 36 | 17 | CR/PR/SD>6 months | 9 | 53 | 19 |
Hodeib et al.[39] | Rare Gynecological Cancers | NGS | 22 | 1 | 5 | 1 | Clinical response | 1 | 100 | 5 |
Bryce et al.[40] | Refractory Solid Cancers | NGS | 141 | 29 | 21 | 29 | Clinical response | 13 | 45 | 9 |
TOTAL | | | 2675 | 499 | 19 | 488 | | 166 | 34 | 6 |
PCDx™ |
Radovich et al.[45] | Refractory Solid Tumors | IHC, NGS | 168 | 44 | 26 | 44 | PFS Ratio ≥ 1.3 | 19 | 43 | 11 |
TOTAL | | | 168 | 44 | 26 | 44 | | 19 | 43 | 11 |